Lactobacillus fermentum – LF10 (DSM 19187)

Tabella dei contenuti

Clinical indications

antipathogenic activity, vaginal candidiasis, Vaginal health

Area of use

Gynecology blend | Vaginal candidiasis

  • Lactobacillus acidophilus – LA02 (DSM 21717)
  • Lactobacillus fermentum – LF10 (DSM 19187)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1,2) 400 million CFU/strain/tablet + Carbon dioxide + FOS + Arabinogalactan


FUNCTIONALITY
Vaginal health • Inhibition of Candida strains • Innovative effervescent slow release tablet for enhanced delivery and activity of lactobacilli • Counteraction of Candida vulvovaginitis

Scientific support

Human clinical trials
1) Vicariotto F. et al. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012; 46 Suppl:S73-80.
2) Murina F. et al. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a Slow-release Vaginal Product be Useful for Prevention of Recurrent Vulvovaginal Candidiasis? J Clin Gastroenterol. 2014; 48:S102-105.

In vitro study
Deidda F. et al. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. J Clin Gastroenterol. 2016; 50:S171-S174.


Gynecology blend | Vaginal candidiasis

  • Lactobacillus plantarum – LP02 (LLMG P-21020)
  • Lactobacillus fermentum – LF10 (DSM 19187)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
500 million per strain


FUNCTIONALITY
Vaginal health • Counteraction of Candida vulvovaginitis • Counteraction of Candida vulvovaginitis including recurrence

Scientific support

Clinical study
Murina F. et al. Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. New Microbiologica, 41,3, 220-224, 2018, ISN 1121-7138.


Gut-brain blend | ALS

  • Lactobacillus fermentum – LF10 (DSM 19187)
  • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)
  • Lactobacillus plantarum – LP01 (LMG P-21021)
  • Lactobacillus salivarius – LS03 (DSM 22776)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
LF10 4 billion cfu + LDD01 2 billion cfu + LP01 2 billion cfu + LS03 2 billion cfu

Scientific support

Human clinical trial
Mazzini L. et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol, Vol 00, N 00, 2018.
Clinical studies on-going